FDA grants orphan drug designation to HLX22 for gastric cancer, with a phase 2 trial showing improved progression-free ...

Less than one-quarter of oncologists surveyed indicated that every one of their patients with advanced gastric or gastroesophageal junction cancers received biomarker testing consistent with practice ...

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

Researchers conducted a meta-analysis of studies to explore the efficacy and safety of pembrolizumab alone and in combination with chemotherapy for the treatment of gastric and GEJ cancers.

Yelena Y. Janjigian, MD, discusses the long-term survival data from the KEYNOTE-811 trial of pembrolizumab plus trastuzumab ...

Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer ...

The trial will include patients with locally advanced or metastatic HER2-positive, PD-L1-positive gastric or gastroesophageal junction cancer.

A Peter Mac-led international clinical trial has found a way to personalize treatment for gastroesophageal cancer, ...

Yelena Y. Janjigian, MD, discusses the standard approval of pembrolizumab plus trastuzumab and chemotherapy for the treatment ...

The Business Research Company's Gastroesophageal Junction Adenocarcinoma Therapeutics Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 Updated 2025 Market Reports Released ...